415 related articles for article (PubMed ID: 19203728)
1. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.
Giralt S; Ballen K; Rizzo D; Bacigalupo A; Horowitz M; Pasquini M; Sandmaier B
Biol Blood Marrow Transplant; 2009 Mar; 15(3):367-9. PubMed ID: 19203728
[TBL] [Abstract][Full Text] [Related]
2. Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant.
Ghosh N; Ahmed S; Ahn KW; Khanal M; Litovich C; Aljurf M; Bacher VU; Bredeson C; Epperla N; Farhadfar N; Freytes CO; Ganguly S; Haverkos B; Inwards D; Kamble RT; Lazarus HM; Lekakis L; Murthy HS; Nishihori T; Ramakrishnan P; Rizzieri DA; Yared JA; Kharfan-Dabaja MA; Sureda A; Hamadani M
JAMA Oncol; 2020 Jul; 6(7):1011-1018. PubMed ID: 32496525
[TBL] [Abstract][Full Text] [Related]
3. A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease.
Khandelwal P; Bleesing JJ; Davies SM; Marsh RA
Biol Blood Marrow Transplant; 2016 Nov; 22(11):2011-2018. PubMed ID: 27543157
[TBL] [Abstract][Full Text] [Related]
4. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen.
Marsh RA; Rao MB; Gefen A; Bellman D; Mehta PA; Khandelwal P; Chandra S; Jodele S; Myers KC; Grimley M; Dandoy C; El-Bietar J; Kumar AR; Leemhuis T; Zhang K; Bleesing JJ; Jordan MB; Filipovich AH; Davies SM
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1460-70. PubMed ID: 25865646
[TBL] [Abstract][Full Text] [Related]
5. Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison.
Sharma P; Pollyea DA; Smith CA; Purev E; Kamdar M; Haverkos B; Sherbenou D; Rabinovitch R; Hammes A; Gutman JA
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1671-1677. PubMed ID: 29684565
[TBL] [Abstract][Full Text] [Related]
6. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
7. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
[TBL] [Abstract][Full Text] [Related]
8. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S; Michallet M; Porcher R; Attal M; Ades L; Bernard M; Blaise D; Tabrizi R; Garban F; Cassuto JP; Chevalier P; Facon T; Ifrah N; Renaud M; Tilly H; Vernant JP; Kuentz M; Bourhis JH; Bordigoni P; Deconinck E; Lioure B; Socié G; Milpied N;
Haematologica; 2007 May; 92(5):627-34. PubMed ID: 17488686
[TBL] [Abstract][Full Text] [Related]
10. Post-Transplant CD34
Chandra S; Bleesing JJ; Jordan MB; Grimley MS; Khandelwal P; Davies SM; Edwards S; Leemhuis T; Marsh RA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1527-1529. PubMed ID: 29555312
[TBL] [Abstract][Full Text] [Related]
11. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma.
Kekre N; Marquez-Malaver FJ; Cabrero M; Piñana J; Esquirol A; Soiffer RJ; Caballero D; Terol MJ; Martino R; Antin JH; Lopez-Corral L; Solano C; Armand P; Pérez-Simon JA
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1808-1815. PubMed ID: 27470290
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
Hari P; Carreras J; Zhang MJ; Gale RP; Bolwell BJ; Bredeson CN; Burns LJ; Cairo MS; Freytes CO; Goldstein SC; Hale GA; Inwards DJ; Lemaistre CF; Maharaj D; Marks DI; Schouten HC; Slavin S; Vose JM; Lazarus HM; van Besien K
Biol Blood Marrow Transplant; 2008 Feb; 14(2):236-45. PubMed ID: 18215784
[TBL] [Abstract][Full Text] [Related]
15. Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
Jain T; Kunze KL; Temkit M; Partain DK; Patnaik MS; Slack JL; Khera N; Hogan WJ; Roy V; Noel P; Leis JF; Sproat LZ; Fauble V; Mesa RA; Palmer J
Bone Marrow Transplant; 2019 Feb; 54(2):204-211. PubMed ID: 29795431
[TBL] [Abstract][Full Text] [Related]
16. Defining the intensity of conditioning regimens: working definitions.
Bacigalupo A; Ballen K; Rizzo D; Giralt S; Lazarus H; Ho V; Apperley J; Slavin S; Pasquini M; Sandmaier BM; Barrett J; Blaise D; Lowski R; Horowitz M
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1628-33. PubMed ID: 19896087
[TBL] [Abstract][Full Text] [Related]
17. R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Modi D; Kim S; Surapaneni M; Ayash L; Alavi A; Ratanatharathorn V; Deol A; Uberti JP
Biol Blood Marrow Transplant; 2020 Apr; 26(4):683-690. PubMed ID: 31682979
[TBL] [Abstract][Full Text] [Related]
18. Mixed chimerism and graft loss in pediatric recipients of an alemtuzumab-based reduced-intensity conditioning regimen for non-malignant disease.
Oshrine BR; Olson TS; Bunin N
Pediatr Blood Cancer; 2014 Oct; 61(10):1852-9. PubMed ID: 24939325
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
20. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol.
Ramzi M; Mohamadian M; Vojdani R; Dehghani M; Nourani H; Zakerinia M; Haghighinejad H
Exp Clin Transplant; 2012 Apr; 10(2):163-7. PubMed ID: 22432762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
